{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:31:24Z","timestamp":1767173484231,"version":"build-2238731810"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Real-world evidence comparing health care resource use (HRU) and costs between novel targeted therapies among patients with chronic lymphocytic leukemia (CLL) is lacking. We compared all-cause and CLL-specific HRU and costs between patients initiated on B-cell lymphoma 2 inhibitor (venetoclax)\u2013 or Bruton tyrosine kinase inhibitor (BTKi)\u2013based regimens in the second-line (2L) setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This is a retrospective observational study using Optum Clinformatics Data Mart of adult patients with CLL\/small lymphocytic lymphoma who received 2L venetoclax- or BTKi-based regimens (January 2018-December 2021) for the first time and had \u2265one CLL diagnostic claim after 2L initiation and \u2265two claims for venetoclax or BTKi. Baseline characteristics were balanced using stabilized inverse probability of treatment weights. Mean monthly cost difference (MMCD) between cohorts for all-cause and CLL-specific per patient per month (PPPM) costs was estimated. Rates of PPPM-HRU were compared between cohorts using rate ratios (RRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 280 patients, median age 75.5 years, 64.6% and 35.4% received BTKi- versus venetoclax-based regimens, respectively. Most BTKi-treated patients received monotherapy (88.4%), whereas 62.3% of venetoclax-treated patients received combination therapy with anti-CD20 agents. The median duration of 2L therapy was 11.6 and 11.0 months for BTKi versus venetoclax cohorts, respectively. All-cause total costs were lower for venetoclax versus BTKi (MMCD [SE], $\u20132,497.64 [$1,006.77] in US dollars (USD); P = .01), driven by lower medication costs offsetting medical costs; trends were similar for CLL-specific estimates. Outpatient HRU was higher for venetoclax versus BTKi (RR all-cause: 1.22 versus CLL-specific: 1.64).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Venetoclax was associated with total monthly cost savings versus BTKis, illustrating the economic value of time-limited venetoclax-based regimens in the 2L setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op.23.00630","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:59:12Z","timestamp":1713283152000},"page":"1132-1139","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor\u2013Based Regimens in the Second-Line Setting"],"prefix":"10.1200","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7243","authenticated-orcid":true,"given":"Bita","family":"Fakhri","sequence":"first","affiliation":[{"name":"Stanford University, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nnadozie","family":"Emechebe","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0329-3465","authenticated-orcid":true,"given":"Beenish S.","family":"Manzoor","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dureshahwar","family":"Jawaid","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Alhasani","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Edwards","sequence":"additional","affiliation":[{"name":"Lowell General Hospital, Lowell, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-9649","authenticated-orcid":true,"given":"Hande H.","family":"Tuncer","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.96"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw547"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.10.105"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0715-5"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00258"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04600-1"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5928.5928"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00671-z"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137050"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2856"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1929894"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1501351"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0772-3"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20095"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.08.004"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2268"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3855"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1444478"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.25270\/jcp.2022.06.1"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004922"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00919-1"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.11.1532"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123706"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7305"},{"key":"b29","first-page":"S77","volume":"62","author":"Dine J","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5805"}],"updated-by":[{"DOI":"10.1200\/op.24.00351","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000}}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.23.00630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T18:03:40Z","timestamp":1723572220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.23.00630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1200\/OP.23.00630"],"URL":"https:\/\/doi.org\/10.1200\/op.23.00630","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2023-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}